Attached files
| file | filename |
|---|---|
| EX-99.4 - LETTER AGREEMENT - Brickell Biotech, Inc. | d277863dex994.htm |
| EX-99.3 - LETTER AGREEMENT - Brickell Biotech, Inc. | d277863dex993.htm |
| EX-99.1 - ADDITIONAL DISCLOSURE - Brickell Biotech, Inc. | d277863dex991.htm |
| EX-99.2 - LETTER AGREEMENT - Brickell Biotech, Inc. | d277863dex992.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 5, 2012
VICAL INCORPORATED
(Exact name of registrant as specified in charter)
| Delaware | 000-21088 | 93-0948554 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) | ||
| 10390 Pacific Center Court San Diego, California |
92121-4340 | |||
| (Address of principal executive offices) | (Zip Code) | |||
Registrant’s telephone number, including area code: (858) 646-1100
Not Applicable.
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
In this report, “Vical,” “we,” “us” and “our” refer to Vical Incorporated.
| Item 2.02 | Results of Operations and Financial Condition. |
The disclosure contained under the heading “Program Updates and Recent Developments – Year-End Cash and Investments” on Exhibit 99.1 to this Form 8-K is incorporated herein by reference.
| Item 8.01 | Other Events. |
We are filing certain information for the purpose of updating aspects of the description of our business contained in our other filings with the Securities and Exchange Commission. A copy of this additional disclosure is attached as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. |
Description | |
| 99.1 | Additional Disclosure. | |
| 99.2 | Letter agreement dated July 5, 2011, related to the License Agreement dated December 7, 2001, between the Company and CytRx Corporation. | |
| 99.3 | Letter agreement dated July 7, 2011, related to the Exclusive License Agreement dated February 3, 2003, between the Company and City of Hope. | |
| 99.4 | Letter agreement dated July 12, 2011, related to the U.S. License Agreement dated July 12, 2011, between the Company and Astellas Pharma Inc. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| VICAL INCORPORATED | ||||||
| Date: January 5, 2012 | By: | /s/ JILL M. BROADFOOT | ||||
| Jill M. Broadfoot | ||||||
| Senior Vice President, Chief Financial Officer and Secretary | ||||||